Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer
12:13pm, Wednesday, 08'th Jan 2025
The latest dividend declarations, combined with stock price movements, have pushed PFE's yield to be almost twice as JNJ's. But I want to caution you to look beyond yield (and P/E too) and examine oth
Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J's com
Johnson & Johnson: A Potential Beneficiary Of A Great Rotation
10:28pm, Tuesday, 07'th Jan 2025
Johnson & Johnson's stagnant price and bond-like behavior make it an income investment, but a market shift could boost its appeal in 2025. Value stocks, including JNJ, may gain favor as growth stocks'
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
06:51pm, Tuesday, 07'th Jan 2025
Johnson & Johnson (JNJ) reachead $146.18 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.
Buy 1 January S&P 500 Dividend Aristocrat Out Of 38 'Safer'
03:32pm, Tuesday, 07'th Jan 2025
**Investment Thesis:** January's top-yielding Aristocrats include Franklin Resources, Realty Income, Amcor, Kenvue, and Hormel, offering dividends from $1K investments exceeding single share prices. *
J&J lung cancer treatment extends lives versus AstraZeneca drug
01:36pm, Tuesday, 07'th Jan 2025
Johnson & Johnson (NYSE:JNJ) has said its chemotherapy-free combination extended lung cancer patients' lives compared to AstraZeneca PLC (LSE:AZN)'s Tagrisso drug in a head-to-head study. The combinat
Johnson & Johnson: I'm Saying Yes To This Mess
11:00am, Tuesday, 07'th Jan 2025
JNJ's long-term buy rating is based on its blue-chip pedigree, profitability, and diverse revenue lines, despite recent price stagnation and litigation risks. I emphasize adapting to market conditions
J&J says its lung cancer drug combination keeps people alive longer
10:59am, Tuesday, 07'th Jan 2025
Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca's Tagrisso in a clinical trial. J&J is trying to supp
J&J's combo extends patients' lives in head-to-head study with AstraZeneca's drug
08:10am, Tuesday, 07'th Jan 2025
Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending lives of patients with a type of lung cancer, compared to AstraZeneca's block
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer RARITAN
My Top 10 Dividend Paying Buy-And-Hold Stocks For 2025
06:00pm, Monday, 06'th Jan 2025
I will introduce you to my top 10 dividend paying buy-and-hold stocks that I would keep in my portfolio for at least the next 10 years. While some of these companies pay a relatively attractive divide
Big Blue Chip Dividends? Try These ‘Dogs' Up To 6.8%
11:49am, Saturday, 04'th Jan 2025
The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays.
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (January 2025)
08:00am, Saturday, 04'th Jan 2025
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (January 2025)
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
03:46am, Friday, 03'rd Jan 2025
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.
5 Low-Leverage Stocks Worth Adding to Your Portfolio in 2025
04:06pm, Thursday, 02'nd Jan 2025
The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy FOX, NWG, ATR, JNJ and REVG.
